Ozempic, Semaglutide

Meet ‘Super’ Ozempic: Higher Dose Semaglutide Leads to Even Greater Weight Loss In Major Trial
People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.
Novo Nordisk says its obesity drug in higher dose shows 20.7% weight loss
Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight patients lower their weight by 20.7%.
Medicare targets popular weight loss drugs Ozempic, Wegovy for price negotiations
The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, diabetes and asthma.
Novo Nordisk touts 'superior' weight loss results in study of high-dose Wegovy
In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is rolling out new data on a higher-dose injection in obesity. | In the phase 3b STEP UP study,
Novo Nordisk Links High-Dose Wegovy to Increased Weight Loss in Phase III Trial
Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP trial to evaluate the effect of increasing the maximum dose to 7.2 mg. The trial randomized 1,407 adults with obesity, but not diabetes, to receive either 7.2 mg or 2.4 mg of semaglutide or placebo.
Ozempic 3.0? This drug causes the greatest weight loss — by far
Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective for obese adults who do not have diabetes.
Medicare to negotiate price of Ozempic, Wegovy weight-loss drugs
The Biden administration moved Friday to negotiate the prices Medicare pays for the blockbuster weight-loss drugs Ozempic and Wegovy, medications costing the massive government health program billions of dollars a year.
New Weight Loss Drugs May Fight Obesity-Related Cancer, Too
Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.
US targets Novo Nordisk's Ozempic and Wegovy for Medicare price talks
Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027, the U.S. government said on Friday.
The most and least expensive weight loss drugs, ranked
Sales of blockbuster weight-loss drugs have surged in 2024 and are projected to continue rising in the coming years. The medications, which belong to the class of drugs called GLP-1s and were popularized by the diabetes treatment Ozempic,
Tripling Wegovy dosage leads to more weight loss, Novo Nordisk trial shows
Tripling the dosage of the Wegovy weight-loss drug leads to more weight loss, Novo Nordisk said Friday. The Danish drugmaker announced results from a Phase 3B trial of semaglutide at a 7.2 milligram dosage,
Ozempic, Wegovy among drugs selected for Medicare's price negotiations
The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...
Oral Ozempic and a ‘miracle’ pill imitating the keto diet – a new era of weight loss is here
The race is on for new drugs that suppress appetite, improve glucose regulation and can replace injections. But do they ...
'I feel blessed to get weight-loss jab' - but can the NHS afford it for all?
We meet some of the first NHS patients, as expert says funding everyone eligible would "bankrupt" the service.
Hosted on MSN1d
Could Ozempic Be Causing Sudden Blindness? New Research Suggests a Link
Are you an Ozempic user, or considering starting on the drug? You may want to read this. Recent research is cause for concern ...